

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

FRIDAY, FEBRUARY 2, 2024

## AGENDA

- 7:00 am IN-PERSON: Check In, Continental Breakfast, Visit Exhibits and Experts
- 7:45 pm VIRTUAL: Log in to Virtual Conference
- 8:00 am Welcome and Introductions  
[Edward A. Stadtmauer, MD](#) | Activity Director  
[Robert H. Vonderheide, MD, DPhil](#) | Director, Abramson Cancer Center
- 8:10 am Keynote Address: Use and Interpretation of Molecular Genetics in Blood Cancers?  
[Jennifer J.D. Morrisette, PhD](#) | Pathology and Laboratory Medicine

## NEW THERAPIES AND CURRENT PATIENT MANAGEMENT OF LYMPHOMAS

MODERATOR: [Stephen J. Schuster, MD](#) | Activity Co-Director

- 8:40 am Novel Therapies in Follicular and Marginal Zone Lymphomas  
[Jordan S. Carter, MD](#)
- 8:55 am Advances in CLL and Mantle Cell Lymphoma  
[Elise A. Chong, MD](#)
- 9:10 am Updates in Management of Hodgkin Lymphoma  
[Jakub Svoboda, MD](#) | Activity Co-Director
- 9:25 am Therapeutic Advances in T-Cell Lymphomas  
[Stefan K. Barta MD, MS, MRCPCUK](#)
- 9:40 am Targeted Therapy of Aggressive B-Cell Lymphomas  
[Daniel J. Landsburg, MD](#)

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**9:55 am**      **Evolving Role of Immune Modulation Therapies including CART and Bispecific Antibodies and New Antibodies in Lymphoma Management**

[Sunita D. Nasta, MD, FACP](#)

**10:15 am**      **Panel Discussion**

**MODERATOR:** [Stephen J. Schuster, MD](#) | Activity Co-Director

**PANEL:**

[Stefan K. Barta MD, MS, MRCPCUK](#)

[Jordan S. Carter, MD](#)

[Elise A. Chong, MD](#)

[Michael R. Cook, MD](#)

[Gamil S. Hanna, MD](#)

[Mitchell E. Hughes, Pharm.D., BCOP](#) | Oncology Pharmacy

[Daniel J. Landsburg, MD](#)

[Danielle Land, MSN, CRNP](#)

[Sunita D. Nasta, MD, FACP](#)

[John P. Plastaras, MD, PhD](#) | Radiation Oncology

[Colin James Thomas, MD](#)

[Emily Tomasulo, DO](#)

[Jakub Svoboda, MD](#) | Activity Co-Director

**10:45 am**      **Break and Visit Exhibits**

## **UPDATE IN BLOOD AND MARROW TRANSPLANTATION AND CELLULAR THERAPY**

**MODERATOR:** [Nasheed M. Hossain, MD](#) | Activity Co-Director

**10:55 am**      **Updates in Cellular Therapy for Sickle Cell Disease**

[Scott A. Peslak, MD, PhD](#)

**11:10 am**      **Alternative Donor Options**

[Shannon R. McCurdy, MD](#)

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**11:25 am**      **New Approaches to Preventing and Treating GVHD**

[Pashna Munshi, MD](#)

**11:40 am**      **Panel Discussion**

**MODERATOR:** [Nasheed M. Hossain, MD](#) | Activity Co-Director

**PANEL:**

[Noelle V. Frey, MD](#)

[Nasheed M. Hossain, MD](#) | Activity Co-Director

[Shannon R. McCurdy, MD](#)

[Linda Perry, PA-C](#)

[John P. Plastaras, MD, PhD](#) | Radiation Oncology

**11:55 am**      **Lunch Break and Visit Exhibits**

## **UPDATE ON PATIENT CARE TREATMENT STRATEGIES IN LEUKEMIA**

**MODERATOR:** [Catherine E. Lai, MD, MPH](#) | Activity Co-Director

**12:25 pm**      **Emerging Treatment Options for AML**

[Alexander E. Perl, MD](#)

**12:40 pm**      **MDS / Hereditary Myeloid Disorders**

[Ximena Jordan-Bruno, MD](#)

**12:55 pm**      **Update in CML and Myeloproliferative Disease**

[Elizabeth O. Hexner, MD, MSTR](#)

**1:10 pm**      **Immunotherapies of Acute Leukemias**

[Catherine E. Lai, MD, MPH](#) | Activity Co-Director

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

1:25 pm

**Panel Discussion**

**MODERATOR:** [Catherine E. Lai, MD, MPH](#) | Activity Co-Director

**PANEL:**

[Alison Carulli, PharmD](#) | Oncology Pharmacy

[Elizabeth O. Hexner, MD, MSTR](#)

[Ximena Jordan-Bruno, MD](#)

[Lindsay M. Lee, MSN, CRNP](#)

[Selina M. Luger, MD](#)

[Alexander E. Perl, MD](#)

[John P. Plastaras, MD, PhD](#) | Radiation Oncology

[Sunil Saroha, MD](#)

[Catherine E. Lai, MD, MPH](#) | Activity Co-Director

## **CONTROVERSIES AND UPDATE FOR PATIENT CARE IN MULTIPLE MYELOMA**

**MODERATOR:** [Edward A. Stadtmauer, MD](#) | Activity Director

1:45 pm

**Smoldering Myeloma and Amyloidosis**

[Sandra P. Susanibar-Adaniya, MD](#)

2:10 pm

**Initial Therapy for Multiple Myeloma Including Transplant**

[Alfred L. Garfall, MD, MS](#)

2:30 pm

**Role of Immunotherapy for Myeloma**

[Adam D. Cohen, MD](#)

2:50 pm

**Experimental Therapies for Relapsed Myeloma**

[Dan T. Vogl, MD, MSCE](#)

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

3:10 pm

Panel Discussion

**MODERATOR:** [Edward A. Stadtmauer, MD](#) | Activity Co-Director

**PANEL:**

[Shivani Bakhshi, DO](#)

[Adam D. Cohen, MD](#)

[Alfred L. Garfall, MD](#)

[Shivani Kapur, MD](#)

[Oxana Megherea, PharmD](#) | Oncology Pharmacy

[John P. Plataras, MD, PhD](#) | Radiation Oncology

[Leah R. Power, MSN, CRNP](#)

[Sandra P. Susanibar-Adaniya, MD](#)

[Dan T. Vogl, MD, MSCE](#)

[Adam Waxman, MD, MS](#)

4:00 PM

Adjourn

## Post Conference Details

After the conference has concluded, all attendees will receive an email from Penn CME with instructions on how to complete the post-test, evaluation, claim credit and obtain a certificate. Look for the email the week after the conference.

If you missed the Pre-Test, you will still be eligible to obtain your certificate after you complete the Post-Test and Evaluation. A Certificate of Participation is available to attendees who are not physicians.

## Meeting Videos

Website: [PennMedicine.org/Abramson/BloodCME2024](https://PennMedicine.org/Abramson/BloodCME2024)

*\*Recordings from the meeting will be available Thursday February 8<sup>th</sup>, 2024, through February 2025.*

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

## Overview

This course is a comprehensive review of hematologic malignancies focusing on research developments over the preceding year and their application to the patient care journey. Didactic presentations will include case discussion with Penn faculty and community experts. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care. Participants will leave with up-to-date, practical information which will have immediate clinical application.

## Learning Objectives

**At the completion of this course, participants should be able to:**

- Identify clinical features, including differential diagnoses for the various hematologic malignancies
- Implement strategies that incorporate state-of-the-art genomic analysis for hematologic malignancies
- Identify new data for hereditary myeloid disorders
- Select appropriate hematologic malignancy patients for immunotherapy
- Select appropriate clinical trials for hematologic malignancies
- Identify the major patient management issues experienced by the interprofessional care team associated with hematologic malignancies
- Apply new strategies for incorporating therapies that target metabolism in blood cancers

## Who Should Attend

This activity has been designed for hematologists, medical and radiation oncologists, primary care physicians, pathologists, hematology/oncology fellows, oncology nurses, oncology social workers, and other healthcare professionals involved in the treatment of patients with blood cancer.

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

## Accreditation



In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## Designation of Credit

**PHYSICIANS:** Penn Medicine designates this live activity for a maximum of 7.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**NURSES:** The program awards 7.25 NCPD hours.

## Penn Medicine Speakers

### Activity Director

**Edward A. Stadtmauer, MD**

Roseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor  
Chief, Hematologic Malignancies Section

Division of Hematology Oncology

Co-Leader, Hematologic Malignancies Research Program

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

## Activity Co-Directors

### **Catherine E. Lai, MD, MPH**

Associate Professor of Medicine (Hematology Oncology)  
Physician Leader, Leukemia Clinical Research Unit  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine Philadelphia, PA, USA

### **Nasheed M. Hossain, MD**

Assistant Professor of Medicine (Hematology Oncology)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine Philadelphia, PA, USA

### **Patricia Mangan, RN, MSN, CRNP, APRN-BC \***

Nurse Lead, Hematologic Malignancies Program  
Abramson Cancer Center  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine Philadelphia, PA, USA

### **David L. Porter, MD**

Jodi Fisher Horowitz Professor of Leukemia Care Excellence  
Director, Cell Therapy and Transplant  
Abramson Cancer Center  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine Philadelphia, PA, USA

### **Keith W. Pratz, MD**

Associate Professor of Medicine (Hematology Oncology)  
Director, Leukemia Program  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine Philadelphia, PA, USA

### **Stephen J. Schuster, MD**

Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research  
Director, Lymphoma Program  
Director, Lymphoma Translational Research  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine Philadelphia, PA, USA

### **Jakub Svoboda, MD**

Associate Professor of Medicine (Hematology Oncology)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine Philadelphia, PA, USA

\*Nurse Planner

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**FRIDAY, FEBRUARY 2, 2024**

## Faculty

### **Shivani J. Bakhshi, DO**

Attending Physician  
Penn Medicine  
Philadelphia, PA, USA

### **Stefan K. Barta, MD, MS, MRCPCUK**

Associate Professor of Clinical Medicine (Hematology Oncology)  
Director, T-Cell Lymphoma Program  
Executive Officer, AIDS Malignancy Consortium  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

### **Jordan S. Carter, MD**

Assistant Professor of Clinical Medicine (Hematology Oncology)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

### **Alison Carulli, PharmD**

Clinical Pharmacist (Hematology Oncology)  
Perelman School of Medicine at the University of Pennsylvania/ Penn Medicine  
Philadelphia, PA, USA

### **Elise A. Chong, MD**

Assistant Professor, Medicine (Hematology Oncology)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

### **Adam D. Cohen, MD**

Associate Professor, Medicine (Hematology Oncology)  
Director, Myeloma Immunotherapy  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**Michael R. Cook, MD**

Assistant Professor of Clinical Medicine (Hematology-Oncology)  
Perelman School of Medicine at the University of Pennsylvania/ Penn Medicine  
Philadelphia, PA, USA

**Noelle V. Frey, MD, MSCE**

Constance and Sankey Williams Associate Professor (Hematology Oncology)  
Director of Clinical Cellular Therapy, Cell and Transplant Therapy Program  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Alfred L. Garfall, MD, MS**

Assistant Professor of Medicine (Hematology Oncology)  
Director, Autologous Hematopoietic Stem Cell Transplantation  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Gamil S. Hanna, MD**

Clinical Assistant Professor of Medicine (Hematology Oncology)  
Medical Director, Infusion Services, Penn Medicine Cherry Hill  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Elizabeth O. Hexner, MD, MSTR**

Associate Professor of Medicine (Hematology Oncology)  
Medical Director, Center for Cellular Immunotherapies  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

# **2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT**

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**Mitchell E. Hughes, PharmD, BCOP**

Clinical Pharmacy Specialist (Hematology/Oncology/Cellular Therapy)

Lymphoma Program and Lymphoma Translational Research

Perelman Center for Advanced Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA USA

**Ximena Jordan-Bruno, MD**

Assistant Professor of Clinical Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Shivani Kapur, MD**

Assistant Professor of Clinical Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Danielle Land, MSN, CRNP**

Nurse Practitioner (Hematology Oncology)

Abramson Cancer Center

University of Pennsylvania

Philadelphia, PA, USA

**Daniel K. Landsburg, MD**

Associate Professor of Clinical Medicine (Hematology Oncology)

Vice Chief of Quality and Safety, Division of Hematology/Oncology

Medical Director of Infusion Services, Hospital of the University of Pennsylvania

Physician Leader, Oncology Clinical Effectiveness Team

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Lindsay M. Lee, CRNP**

Nurse Practitioner (Hematology Oncology)

Abramson Cancer Center

University of Pennsylvania

Philadelphia, PA, USA

# **2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT**

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**Selina M. Luger, MD**

Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Shannon R. McCurdy, MD**

Assistant Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Oxana Megherea, PharmD**

Clinical Pharmacy Specialist (Oncology)

Penn Medicine

Philadelphia, PA, USA

**Jennifer J.D. Morrissette, PhD**

Associate Professor of Clinical Pathology and Laboratory Medicine

Clinical Director, Center for Personalized Diagnostics

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Pashna N. Munshi, MD**

Associate Professor of Medicine (Hematology Oncology)

University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Sunita D. Nasta, MD**

Professor of Clinical Medicine (Hematology Oncology)

Chair, Clinical Trials Review Monitoring Committee

Chair, Penn Institutional Review Board Associate

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Alexander E. Perl, MD**

Associate Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**Linda M. Perry, MS, PA-C**

Physician Assistant, Cellular Therapy and Transplant  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Scott A. Peslak, MD, PhD**

Assistant Professor of Medicine (Hematology Oncology)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**John P. Plastaras, MD, PhD**

Professor of Radiation Oncology  
Chief, Gastrointestinal/Hematologic Service, Radiation Oncology  
Vice Chair, Strategic Clinical Research, Radiation Oncology  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Leah R. Power, MSN, CRNP**

Nurse Practitioner  
University of Pennsylvania  
Philadelphia, PA, USA

**Sunil Saroha, MD**

Clinician (Hematology Oncology)  
Chester County Hospital - Penn Medicine  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Sandra P. Susanibar-Adaniya, MD**

Assistant Professor of Medicine (Hematology Oncology)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Colin J. Thomas, MD**

Assistant Professor of Clinical Medicine (Hematology-Oncology)  
Penn Medicine  
Philadelphia, PA, USA

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**Emily Tomasulo, DO**

Assistant Professor of Medicine (Hematology Oncology)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Dan T. Vogl, MD, MSCE**

Associate Professor of Medicine (Hematology Oncology)  
Director, Abramson Cancer Center Clinical Research Unit (CRU)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Robert H. Vonderheide, MD, DPhil**

Director, Abramson Cancer Center  
John H. Glick Abramson Cancer Center's Director Professor  
Vice Dean for Cancer Programs, Perelman School of Medicine  
Vice President for Cancer Programs, UPHS  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Adam Waxman, MD**

Assistant Professor of Clinical Medicine (Hematology Oncology)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

## Disclosure of Financial Relationships

Staff in the Office of Continuing Medical and Interprofessional Education (CMIE) (Bruce Brod, MD, MCHI, FAAD, Vaughn Wurst and Belinda Rose, CHCP), and the listed Planning Committee Members (Barbara Lopez, Hyacen Putmon) have reported that they have no financial relationships with any ineligible companies related to the content of this educational activity.

The following faculty and planning committee (\*) members have disclosed that they have no financial relationships with any ineligible companies related to the content of this educational activity.

Shivani J. Bakhshi, DO  
Ximena Jordan Bruno, MD  
Jordan S. Carter, MD  
Alison Carulli, PharmD  
Gamil S. Hanna, MD  
Nasheed M. Hossain, MD\*  
Ximena Jordan-Bruno, MD  
Shivani Kapur, MD  
Lindsay M. Lee, MSN, AHNP, AGACNP

Shannon R. McCurdy, MD  
Oxana Megherea, PharmD, BCOP  
John P. Plastaras, MD, PhD  
Leah R. Power, MSN, CRNP  
Sunil Saroha, MD  
Colin J. Thomas, MD  
Emily Tomasulo, DO  
Robert H. Vonderheide, MD, DPhil  
Adam Waxman, MD, MS

The following planning committee (\*) and faculty members have reported the listed financial relationships with ineligible companies related to the content of their presentations. All financial relationships have been mitigated.

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

## FACULTY NAME

Stefan K Barta, MD

## DISCLOSURE(S)

Consulting Fee-Affirmed (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Pharmaceuticals (J&J)|Consulting Fee-Seattle Genetics (Relationship has ended)|Honoraria-Acrotech|Consulting Fee-Daiichi Sankyo (Relationship has ended)|Honoraria-Kyowa Kirin

Elise Chong, MD

Consulting Fee-Novartis / Amgen (Relationship has ended)|Consulting Fee-Bristol-Myers Squibb (Relationship has ended)|Consulting Fee-Gilead Sciences, Inc (Relationship has ended)|Consulting Fee-Beigene (Relationship has ended)|Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended)|Grant or research support-AbbVie, Inc. |Grant or research support-Genentech

Adam D. Cohen, MD

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Pharmaceuticals (J&J)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Takeda Pharmaceuticals (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Oncceptides (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astra Zeneca Pharmaceuticals (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech|Grant or research support-Genentech|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Seattle Genetics (Relationship has ended)|Grant or research support-Glaxo Smith Kline|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Glaxo Smith Kline|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Arcellix|Grant or research support-Novartis (Advanced Health Media)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Ichnos|Membership on

*(continued)*

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

Michael R Cook, MD

Noelle V. Frey, MD, MSCE

Alfred L L. Garfall, MD, MS

Elizabeth Hexner, MD

Mitchell Hughes, PharmD

Catherine E. Lai, MD, MPH\*

Advisory Committees or Review Panels, Board Membership, etc.-Pfizer, Inc. | Membership on Advisory Committees or Review Panels, Board Membership, etc.-AbbVie, Inc. (Relationship has ended) | Membership on Advisory Committees or Review Panels, Board Membership, etc.-iTeos (Relationship has ended)

Honoraria-Curio Science, A Vaniam Group Company

Consulting Fee-Kite Pharma (Relationship has ended) | Consulting Fee-Autolus (Relationship has ended) | Consulting Fee-Sana Biotechnology (Relationship has ended)

Consulting Fee-Janssen Pharmaceuticals (J&J) | Consulting Fee-Amgen (Relationship has ended) | Grant or research support-Novartis (Advanced Health Media) | Grant or research support-Janssen Pharmaceuticals (J&J) | Grant or research support-Tmunity | Grant or research support-crispr therapeutics | Consulting Fee-Bristol-Myers Squibb (Relationship has ended) | Consulting Fee-Glaxo Smith Kline (Relationship has ended)

Grant or research support-Tmunity Therapeutics | Advisor-AbbVie, Inc. | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Blueprint Medicines | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pharmessentia (Relationship has ended) | Membership on Advisory Committees or Review Panels, Board Membership, etc.-American Board of Internal Medicine

Advisor-AbbVie, Inc. (Relationship has ended) | Grant or research support-HOPA/Acerta Pharma | Advisor-Karyopharm (Relationship has ended) | Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended)

Advisor-Genentech | Advisor-Rigel | Advisor-Taiho Oncology (Relationship has ended) | Advisor-AbbVie, Inc. | Advisor-Novartis (Relationship has ended) | Consulting Fee-Jazz Pharma (Relationship has ended) | Advisor-Pfizer, Inc. (Relationship has ended)

*Continued*

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

Danielle Land, CRNP

Consulting Fee-PDS Biotechnology | Consulting Fee-Macrogenics (Relationship has ended) | Consulting Fee-Astellas (Relationship has ended) | Speakers Bureau-Jazz Pharma (Relationship has ended) | Speakers Bureau-Astellas (Relationship has ended) | Honoraria-OncoLive (Relationship has ended) | Honoraria-BioAscent (Relationship has ended) | Advisor-Daiichi (Relationship has ended)

Speakers Bureau-Astra Zeneca Pharmaceuticals | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Beigene | Speakers Bureau-Janssen Pharmaceuticals (J&J) | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Pharmaceuticals (J&J)

Daniel Landsburg, MD

Grant or research support-Calithera | Honoraria-Novartis (Advanced Health Media) (Relationship has ended) | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis (Advanced Health Media) (Relationship has ended) | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Calithera (Relationship has ended) | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Epizyme (Relationship has ended) | Membership on Advisory Committees or Review Panels, Board Membership, etc.-ADCT (Relationship has ended) | Speakers Bureau-ADCT | Speakers Bureau-Novartis (Advanced Health Media) (Relationship has ended)

Selina Luger, MD

Consulting Fee-Novartis (Relationship has ended) | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Marker | Membership on Advisory Committees or Review Panels, Board Membership, etc.-daichi sankyo (Relationship has ended) | Membership on Advisory Committees or Review Panels, Board Membership, etc.-astellas (Relationship has ended) | Consulting Fee-marker therapeutics (Relationship has ended)

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

Patricia Mangan, MSN, CRNP\*

Honoraria-Janssen Pharmaceuticals (J&J) | Honoraria-Bristol-Myers Squibb | Honoraria-Takeda Pharmaceuticals (Relationship has ended)

Jennifer J.D. Morrissette, PhD

Honoraria-Novartis (Advanced Health Media) (Relationship has ended) | Advisor-AbbVie, Inc. (Relationship has ended) | Honoraria-Bayer (Relationship has ended) | Stocks or stock options, excluding diversified mutual funds of a publicly traded company-ThermoFisher

Pashna N Munshi, MD

Consulting Fee-Incyte Corporation (Relationship has ended) | Speakers Bureau-Incyte Corporation (Relationship has ended) | Speakers Bureau-Gilead Sciences, Inc (Relationship has ended)

Sunita D. Nasta, MD

Grant or research support-Genentech | Grant or research support-Takeda Pharmaceuticals | Grant or research support-AbbVie, Inc. | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck & Co

Alexander E Perl, MD

Consulting Fee-AbbVie, Inc. | Advisor-Immunogen (Relationship has ended) | Advisor-BerGenBio (Relationship has ended) | Advisor-Actinium (Relationship has ended) | Consulting Fee-Astellas | Consulting Fee-Foghorn | Advisor-Bristol-Myers Squibb (Relationship has ended) | Advisor-Genentech | Consulting Fee-Daiichi Sankyo | Advisor-Loxo (Relationship has ended) | Advisor-Syndax (Relationship has ended) | Consulting Fee-Sumitomo Dainippon (Relationship has ended) | Consulting Fee-Forma (Relationship has ended) | Consulting Fee-Leukemia and Lymphoma Society/BeatAML LLC | Grant or research support-AbbVie, Inc. | Grant or research support-Astellas | Grant or research support-Daiichi Sankyo | Grant or research support-Syndax | Grant or research support-FujiFilm (Relationship has ended)

Linda Perry, PA-C

Paid consultant-Kadmon | Speakers Bureau-Sanofi Genzyme | Paid consultant-Incyte Corporation | Speakers Bureau-Incyte Corporation

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

Scott A Peslak, MD, PhD

Grant or research support-Blueprint Medicines|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bluebird Bio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Agios Pharmaceuticals

David Porter, MD\*

Stocks or stock options, excluding diversified mutual funds-Genentech|Honoraria-Novartis (Advanced Health Media) (Relationship has ended)|Honoraria-Bristol-Myers Squibb (Relationship has ended)|Honoraria-Gilead Sciences, Inc (Relationship has ended)|Honoraria-Janssen Pharmaceuticals (J&J) (Relationship has ended)|Honoraria-Jazz (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-DeCART (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bluebird Bio (Relationship has ended)|Honoraria-Kadmon (Relationship has ended)|Grant or research support-Novartis (Advanced Health Media)|Royalties or Patent Beneficiary-Novartis (Advanced Health Media)|Royalties or Patent Beneficiary-Tmunity (Relationship has ended)|Honoraria-Wiley publishing|Honoraria-Am Society for Transplant and Cell Therapy|Advisor-Angiocrine|Advisor-Mirror Biologics|Advisor-Capstan (Relationship has ended)|Advisor-Instill (Relationship has ended)

Keith W. Pratz, MD\*

Advisor-AbbVie, Inc.|Advisor-Bristol-Myers Squibb (Relationship has ended)|Advisor-Novartis / Amgen (Relationship has ended)|Advisor-Jazz Pharmaceuticals (Relationship has ended)|Advisor-Astellas (Relationship has ended)|Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended)|Advisor-Roche (Relationship has ended)

Stephen J. Schuster, MD\*

Consulting Fee-Genentech|Consulting Fee-AstraZeneca|Consulting Fee-BeiGene (Relationship has ended)|Honoraria-Takeda Pharmaceuticals (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Caribou Biosciences|Grant or research support-Genentech|Grant or research support-Genentech|Consulting Fee-Genmab|

*Continued*

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

Consulting Fee-Incyte Corporation | Consulting Fee-Morphosys | Consulting Fee-Janssen Pharmaceuticals (J&J) | Consulting Fee-Kite Pharma | Consulting Fee-Novartis / Amgen | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis / Amgen | Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended) | Consulting Fee-Celgene Corporation | Consulting Fee-Mustang Biotech (Relationship has ended) | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Legend Biotech | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Fate Therapeutics | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nordic Nanovector (Relationship has ended)

Edward A. Stadtmauer, MD\*

Grant or research support-AbbVie, Inc. | Consulting Fee-Glaxo Smith Kline (Relationship has ended) | Consulting Fee-Sanofi Genzyme (Relationship has ended) | Consulting Fee-Bristol-Myers Squibb (Relationship has ended) | Consulting Fee-Amgen (Relationship has ended)

Sandra Susanibar Adaniya, MD

Consulting Fee-Pfizer, Inc.

Jakub Svoboda, MD\*

Grant or research support-Incyte Corporation | Consulting Fee-Incyte Corporation (Relationship has ended) | Grant or research support-Merck & Co (Relationship has ended) | Grant or research support-Pharmacyclics | Consulting Fee-Bristol-Myers Squibb (Relationship has ended) | Grant or research support-Bristol-Myers Squibb | Grant or research support-TG Therapeutics (Relationship has ended) | Consulting Fee-Seattle Genetics (Relationship has ended) | Grant or research support-Seattle Genetics (Relationship has ended) | Consulting Fee-Astra Zeneca Pharmaceuticals | Grant or research support-Astra Zeneca Pharmaceuticals | Consulting Fee-Atara | Consulting Fee-Adaptive | Grant or research support-Adaptive | Grant or research support-Gilead Sciences, Inc | Consulting Fee-Genmab (Relationship has ended)

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

Dan T. Vogl, MD, MPH, MSCE

Consulting Fee-Takeda Pharmaceuticals | Consulting Fee-Glaxo Smith Kline (Relationship has ended) | Consulting Fee-Karyopharm | Grant or research support-Takeda Pharmaceuticals | Grant or research support-Active Biotech | Consulting Fee-CSL Behring (Relationship has ended) | Consulting Fee-Sanofi Genzyme (Relationship has ended) | Consulting Fee-Genentech | Consulting Fee-AbbVie, Inc.

# 2024 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

## Thank you to Our Exhibitors

AbbVie	Kite, A Gilead Company
Acrotech Biopharma	Loxo@Lilly
ADC Therapeutics	Menarini Stemline
Agios Pharmaceuticals	Merck
Alexion	MorphoSys US
Amgen	Novartis - Car-T
Astellas	Novartis - Hematology
AstraZeneca	Pfizer Oncology
BeiGene	Pharmacyclics LLC, An AbbVie Company
Blueprint Medicines	PharmaEssentia Corporation
Bristol Meyers Squibb - Hematology	Rigel Pharmaceuticals
Bristol Meyers Squibb - Cell Therapy	Sanofi - Rare Blood Diseases
Genentech	Sanofi - Hematology Oncology
Genmab	Seagen
GSK	Secura Bio
Incyte	Servier Pharmaceutical
Johnson and Johnson Oncology	Sobi
Karyopharm Therapeutics	Takeda Oncology